Big Tech is pouring an estimated $700b into AI infrastructure this year, and global healthcare is a key proving ground for whether that spend pays off. UK investors are watching closely because hospitals, drug makers and software providers that can turn AI into real efficiency gains may reshape healthcare economics. This article highlights three AI focused healthcare stocks from our screener to help you evaluate the landscape early.
The stocks highlighted below are just a small sample of the idea, and the full screen surfaced 4 more companies with equally compelling AI in healthcare stories that are not covered here. To identify your own favourites across diagnostics, drug development and hospital software, analyze the full Transformative Artificial intelligence (AI) Healthcare Stocks screener .
Haleon (LSE:HLN)
Haleon brings the AI in healthcare theme down to the everyday level, using data tools to refine toothpaste, pain relief and vitamin brands that shoppers already know, while quietly rewiring how a £30.8b consumer health heavyweight runs its operations worldwide.
Haleon sells oral care, pain relief, respiratory and vitamin products across North America, APAC and EMEA and Latam, with revenue of £3.8b, £2.6b and £4.7b respectively. It also has a collaboration with Microsoft to apply AI across product development and supply chains, supporting its £30.8b market value.
"Extending the current productivity and AI programme, which has already delivered 140 basis points of gross margin improvement alongside SKU and formulation reduction, provides room for further structural cost savings that could widen net margins and raise free cash flow beyond what is implied by modest top line growth."
What happens to Haleon's earnings power if a single efficiency lever quietly shifts the balance between modest sales growth and much stronger margins?
If that margin story has your attention, read the full narrative for Haleon to see how Haleon's AI rollout could accelerate earnings power or leave gaps for rivals.
IXICO (AIM:IXI)
IXICO runs an AI-enabled neuroimaging platform that helps drug developers measure brain changes in conditions such as Alzheimer's and Parkinson's disease. This is wrapped into a medical labs and research business generating about £7 million in sales, with the London listed group valued at roughly £17 million.
IXICO plugs AI directly into MRI and PET brain scans so trial sponsors can track subtle disease changes in neurodegenerative studies. This aligns closely with this screener's focus on diagnostic accuracy and faster research. Investor interest is largely about whether that specialist imaging niche can scale before funding costs or continued losses constrain how far pricing or margins can stretch.
That balance can shift fast if IXICO executes. Check the 1 key reward and 3 important warning signs (2 are major!) to see what could accelerate progress or stall it just short.
AstraZeneca (LSE:AZN)
AstraZeneca is a global prescription medicine giant with a heavy focus on oncology, where its work with Tempus and Pathos to build AI powered multimodal cancer models puts it squarely in the precision medicine corner of this screener.
The group generated about US$61.4b from pharmaceuticals and has a market value near £186.1b.
"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."
What happens to AstraZeneca's earnings profile if a single underappreciated constraint quietly limits how far that AI enabled precision oncology push can stretch margins?
To see how that constraint could flip into a margin engine, read the full narrative for AstraZeneca for AstraZeneca and identify what markets may still be overlooking.
Seeking Fresh Alternatives Beyond Healthcare?
Some of the sharpest breakout stories start quietly, then move fast once momentum builds. Scan fresh ideas before they stop flying under the radar for now and get in early.
-
Spot income workhorses with staying power by lining up yield, payout history and balance sheet strength through the curated 1 dividend fortresses before that window tightens.
-
Track early leaders in robotics and automation by scanning the hand picked 91 robotics and automation stocks while valuations still reflect hesitation rather than full conviction.
-
Front run capital flowing into grid upgrades by reviewing the selected 43 power grid technology and infrastructure stocks before this theme is fully caught in mainstream momentum screens.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
